Special Issue – 2017
Special Issue Title: Systematic Reviews on Amphotericin B: Past, Present and Future
Tentative Title Submission Deadline to Guest Editor: 01stMay 2017
Tentative Summary Submission Deadline to Guest Editor: 01st June 2017
Manuscript Submission Deadline to Guest Editor: 15thJuly 2017
Peer Review Due:15th September 2017
Revision Due: 15th October 2017
Notification of Acceptance by the Guest Editor: 15th December 2017
Lead Editor:
Prof. Mohammad Amjad Kamal
Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia
Enzymoics; Novel Global Community Educational Foundation, 7 Peterlee Place, Hebersham, NSW 2770, Australia
Email: eic-Pharmacovigilance@enlivenarchive.org
Guest Editors:
Dr. Ghulam Md Ashraf
King Fahd Medical Research Center King Abdulaziz University, Jeddah, Saudi Arabia
Email: ashraf.gm@gmail.com, gashraf@kau.edu.sa
Dr. Qamar Zia
Department of Biotechnology, Gagan College of Management and Technology, Aligarh, India Interdisciplinary Biotechnology Unit, AMU, Aligarh 202002 UP, India
Email: qamarbiotech@gmail.com
Special Issue Synopsis:
Aims and Scope of Theme Issue:
Amphotericin B (AmB)-deoxycholate micellar formulation, Fungizone®, is the drug of choice for the treatment of unidentified mycotic infections. However, it usage has been marred by long therapeutic regimes and severe side effects. The less toxic lipid associated AmB formulations have been limited by their high expense, with some loss in activity. The quest for decreasing AmB cytotoxicity as well as production cost has resulted in the development of AmB super-aggregate as an alternative to its existing lipid formulations. This special issue will focus on whether AmB is still the gold standard by exploring the toxic side effects of AmB, its mechanistic rationale for antifungal action, its role in potential drug-drug interactions, and management of adverse events associated with AmB. AmB mediated cell death reflects apoptosis-like phenotype, so the role of AmB as a combination therapy with other antifungal agents will be examined. Moreover, anti-biofilm activity of AmB, role of Ambisome, synthesis and biological evaluation of AmB, and superaggregated AmB as a new alternative to minimize toxicity will also be covered. Finally, cost effectiveness of AB and its formulations will be discussed with the focus on the future of AmB in next decade.
Keywords: Amphotericin B; Antifungal; Superaggregation; Therapy; Toxicity
Authors may submit the manuscripts either through http://enlivenarchive.org/submit-manuscript-pharmacovigilance-drug-safety.php or send the submissions as enclosures to pharmacovigilance-drugsafety@enlivenarchive.org